Randox Molecular Diagnostics, UK, with US headquarters in Kearneysville, WVa, offers a range of molecular arrays and assay formats, providing diagnostic, prognostic, and response to therapy solutions for a range of conditions including colorectal cancer, sexually transmitted infections, and respiratory pathogens, among others.
Its multiplex PCR and proprietary Biochip Array Technology is shown in the range of array formats including SNP Genotyping, based on a primer design that can discriminate sequences that differ only at one base; Gene Expression; Pathogen Detection, for rapid, sensitive, multiplex detection of viral, bacterial, and protozoan pathogens; and Mutation Detection.
The company’s sexually transmitted infection (STI) array is capable of simultaneously detecting 10 of the most common STIs from a single patient sample. STIs represent a serious public health issue and as many are asymptomatic, the risk of unhindered spread is increased. Simultaneous screening for multiple STIs will identify specific viral, protozoan, or bacterial pathogens therefore permitting targeted therapy while also detecting secondary infections.
The respiratory pathogens array simultaneously detects up to 22 viral and bacterial infectious agents of the respiratory tract from bronchoalveolar lavage, nasopharyngeal swab, sputum, or saliva. By detecting both viral and bacterial pathogens simultaneously, this array provides a rapid and cost-effective diagnostic tool.
Source: Randox
